Piramal Pharma

Mumbai, India Founded: 1996 • Age: 30 yrs Listed Fortune India 500 · #275
Innovative healthcare solutions are delivered through end-to-end manufacturing capabilities.
Request Access
Report Incorrect Data
Page last updated

About Piramal Pharma

Piramal Pharma is a publicly listed company based in Mumbai (India) founded in 1996. Innovative healthcare solutions are delivered through end-to-end manufacturing capabilities. The company has 8,560 employees. Its chief executive, as recorded, is Peter De Young. Its website piramalpharma.com draws about 19 thousand monthly visits. Its Indian entity Piramal Pharma Limited reported revenue of ₹9,161 Cr. Piramal Pharma offers products and services including Pharma Solutions, Critical Care, and Consumer Healthcare. Its focus areas include Diversified Pharmaceuticals and Drugs.

Company details

Piramal Pharma was established in 1996 in Mumbai, India, as a global pharmaceutical entity. Operations span multiple facilities where a diverse range of products and services is manufactured and supplied. Focus is placed on differentiated pharmaceutical offerings within the healthcare sector. End-to-end capabilities support innovation in drug development and production across international markets.

Piramal Pharma is ranked #275 on the Fortune India 500 (2025).

Recognitions & Rankings of Piramal Pharma

Fortune India 500 2025 edition
Rank#275
Total income
₹9,600 Cr
Profit
₹91 Cr
Last year #276
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#179
Valuation
₹33,910 Cr
2023 #332 2022 #196
  • Headquarters Mumbai, India
  • Employees 8,560
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website piramalpharma.com
  • Social LinkedIn Facebook YouTube
  • Legal Name Piramal Pharma Limited
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹25,454 Cr

    PPLPHARMA · NSE

  • Share Price
    ₹194.99

    +1.99% today

  • Revenue
    ₹8,869 Cr

    FY 2025-26 · -3.1% YoY

  • EBITDA
    ₹704 Cr

    Margin 7.9%

  • Net Profit
    −₹312 Cr

    FY 2025-26 · -451.5% YoY

  • ROE
    -3.8%

    ROCE 2.5%

  • Debt / Equity
    0.65

    Interest cover -267.9x

  • Employee Count
    8,560

Products & Services of Piramal Pharma

Piramal Pharma offers a comprehensive portfolio of products and services, including Pharma Solutions, Critical Care, and Consumer Healthcare.

Pharma Solutions
CDMO

Provides end-to-end drug development and manufacturing services

Critical Care
Hospital Generics

Offers inhaled anesthetics and hospital products globally

Consumer Healthcare
OTC Products

Sells over-the-counter health items like Littles and Lacto Calamine

Apps and channels of Piramal Pharma

its YouTube channel Piramal Pharma Limited has 164 subscribers and 23 videos.

Piramal Pharma Limited
YouTube 164 subscribers 23 videos Autos & Vehicles
Open channel

Videos from Piramal Pharma

The most watched videos on Piramal Pharma's YouTube channel, Piramal Pharma Limited (164 subscribers). Click a video to play it here.

Welcome to Piramal Pharma Limited
3.3K views
Mission and Vision
700 views
Nandini Piramal in conversation with CNBC TV18 following Piramal Pharma's Investor Day 2024
539 views
Our Values
374 views

More on Piramal Pharma Limited.

Funding Insights of Piramal Pharma

  • Total Rounds 1

All 1 funding rounds of Piramal Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2020Post-IPO––
–

Board of directors of Piramal Pharma Limited (Piramal Pharma)

Piramal Pharma Limited is the primary company behind Piramal Pharma. The board of Piramal Pharma Limited currently have 10 directors; the longest-serving is Peter D Deyoung, appointed in 2020. 2 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Peter D Deyoung
DIN 07152550
Whole-time director04 Mar 20206 yrs 7 moPiramal Pharma Limited
Nandini Ajay Piramal
DIN 00286092
Whole-time director04 Mar 20206 yrs 7 moPiramal Pharma Limited
Ramadorai Subramanian
DIN 00000002
Director09 Feb 20215 yrs 8 moPiramal Pharma Limited
Jairaj Manohar Purandare
DIN 00159886
Director09 Feb 20215 yrs 8 moPiramal Pharma Limited
Vivek Valsaraj
DIN 06970246
Whole-time director09 Feb 20224 yrs 8 moPiramal Pharma Limited
Sridhar Gorthi
DIN 00035824
Director30 Mar 20224 yrs 6 moPiramal Pharma Limited
Peter Andrew Stevenson
DIN 09544706
Director30 Mar 20224 yrs 6 moPiramal Pharma Limited
Vibha Paul Rishi
DIN 05180796
Director30 Aug 20224 yrs 1 moPiramal Pharma Limited
Nathalie Ann Leitch
DIN 09557042
Director28 Jan 20251 yr 8 moPiramal Pharma Limited
Amit Jain
DIN 06917608
Director14 May 20251 yr 5 moPiramal Pharma Limited

People of Piramal Pharma

51 people are tracked at Piramal Pharma (29 in leadership, 1 in board & advisors, 21 in team); the tracked headcount is 8,560.

NameRoleGroup
Peter De Young
CEOLeadership
Michael Teague
Executive VP Global Operations at Piramal Critical Care Inc.Leadership
Christopher Leahy
Senior Vice President, FinanceLeadership
Satyajit Tillu
Senior General Manager & Site HeadLeadership
Susie Hodgson
Director Of Finance And ProcurementLeadership
Debashish Chakravorty
Executive Vice President, India FormulationsLeadership
Stuart Needleman
Chief Commercial Officer & Chief Patient Centricity OfficerLeadership
Sujatha Kumar
General Manager L & D Global PharnaLeadership
Yogita Karakkadavath
Chief Manager - Corporate IPLeadership
Deepika Maskara
Global Head - Total Rewards And Corporate HR HeadLeadership
Ravindra Pawar
Deputy Chief ManagerLeadership
Anil Jaiswal
Head Of Human ResourcesLeadership
John Nause
Director, International Compliance/chief Compliance OfficerLeadership
Anagha Deshpande
Vice President Finance & ITLeadership
Abhishek Fanse
Deputy Chief Manager - Human Resources And AdministrationLeadership
Ca Neelam Valani
Chief Manager FinanceLeadership
Puneet Rajput
Chief Human Resources OfficerLeadership
Swapnil Thakkar
Head Of Contract Manufacturing & ProcurementLeadership
Girish Guna
Head - Indirect TaxLeadership
Manish Punjabi
Head - Learning & Development And Campus Talent ManagementLeadership

31 more people are available in the full profile.

Premium access

Complete people profiles for Piramal Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Piramal Pharma

Piramal Pharma is a publicly listed company on the NSE with ticker symbol PPLPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date19 Oct 2022
  • Listed onBSE: 543635
  • Listed entityPiramal Pharma Limited
  • Exchange sectorHealth technology
  • ISININE0DK501011
  • Share price₹195.00 (-0.52% on the day) · 2026-10-14
  • Market capitalisation₹26,121 Cr
  • EPS (diluted, trailing year)₹-2.37
  • Dividend yield0.07%
  • Volume (last session)542,110

Financials of Piramal Pharma

Exchange-reported figures of Piramal Pharma Limited, the listed company behind Piramal Pharma (NSE: PPLPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹8,869 Cr
-3.1% YoY
EBITDA
₹704 Cr
-51.3% YoY
Profit After Tax
−₹312 Cr
-451.5% YoY
Net Worth
₹8,163 Cr
+0.5% YoY
Total Assets
₹14,088 Cr
+6.7% YoY
Total Debt
₹5,675 Cr
+16.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Profit before tax(176)415179(120)485949
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (₹)(2.46)0.690.13(1.56)3.178.40
Balance sheet
Total assets14,08813,20612,82212,61210,9918,780
Net worth8,1638,1257,9116,7746,6975,605
Total debt5,6754,8564,7105,6374,1283,025
Cash & bank1,224501483308329406
Net working capital3,5413,5543,0592,7172,4031,751
Cash flow
Cash from operations1,6538921,005484766598
Cash from investing(820)(488)(416)(1,334)(1,737)(4,464)
Cash from financing(38.98)(441)(422)8187943,977
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2702,7522,1402,0441,9342,7542,2042,242
Revenue growth (YoY)+17.4%-0.1%-2.9%-8.8%-0.9%---
Other income10959.6353.5080.3997.7158.2529.1878.37
EBITDA195285155159107561338342
EBITDA margin+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%+15.2%
Depreciation224218213203197243197192
Interest88.0882.9989.2482.4286.15104103108
Profit before tax(7.46)43.00(93.86)(46.18)(79.02)27366.80120
Tax61.9351.8342.3353.042.6811963.1297.53
Net profit(69.39)(8.83)(136)(99.22)(81.70)1543.6822.59
EPS (₹)(0.52)(0.07)(1.03)(0.75)(0.62)1.160.030.17
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Profit before tax877911508124462687
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (₹)5.275.222.960.583.105.75
Balance sheet
Total assets9,0228,7447,9216,9366,3004,281
Net worth8,1417,4536,7125,2625,1234,101
Total debt7861,2431,1771,6491,164174
Cash & bank57417824264.16137152
Net working capital1,8422,1011,7971,3371,166463
Cash flow
Cash from operations1,32854935871.5224934.72
Cash from investing(318)(552)(635)(435)(1,165)(4,383)
Cash from financing(615)(61.74)4512908964,494
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1251,4891,1961,1279701,6901,2481,284
Revenue growth (YoY)+16.0%-11.9%-4.2%-12.2%-8.8%---
Other income11518496.1520218139.5124.70106
Total expenses1,0081,2511,0561,0009261,2731,0291,032
EBITDA11723814012744.33417219253
EBITDA margin+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%+19.7%
Depreciation65.7370.1264.6961.2559.4461.1755.4653.61
Interest16.3619.5016.8420.3823.2330.5629.1729.95
Profit before tax149332155247143364159276
Tax36.0070.2226.0251.0829.4487.0940.6165.65

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2702,7522,1402,0441,9342,7542,2042,242
Revenue growth (YoY)+17.4%-0.1%-2.9%-8.8%-0.9%---
Other income10959.6353.5080.3997.7158.2529.1878.37
EBITDA195285155159107561338342
EBITDA margin+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%+15.2%
Depreciation224218213203197243197192
Interest88.0882.9989.2482.4286.15104103108
Profit before tax(7.46)43.00(93.86)(46.18)(79.02)27366.80120
Tax61.9351.8342.3353.042.6811963.1297.53
Net profit(69.39)(8.83)(136)(99.22)(81.70)1543.6822.59
EPS (₹)(0.52)(0.07)(1.03)(0.75)(0.62)1.160.030.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
Other income292208235279335230
Total expenses8,1657,7067,0386,4605,6254,887
Employee cost2,4162,3072,0301,8961,5891,468
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Depreciation831816741677586545
Interest341422448344198163
Profit before tax(176)415179(120)485949
Tax15032416166.31109114
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (₹)(2.46)0.690.13(1.56)3.178.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8356,8016,5885,5805,5114,610
Shareholders' funds (net worth)8,1638,1257,9116,7746,6975,605
Minority interest0.000.000.000.000.000.00
Secured loans5,4704,5904,5365,4973,9812,601
Unsecured loans204266174140146424
Total debt5,6754,8564,7105,6374,1283,025
Total liabilities14,08813,20612,82212,61210,9918,780
Assets
Gross block14,82913,07712,09910,8429,5108,153
Net block8,6848,1337,9907,4696,8796,105
Capital work in progress1,1009771,1161,4191,172627
Investments437291385639267123
Inventories3,0642,3132,1761,6811,3891,232
Sundry debtors2,1582,3502,1341,7991,7851,575
Cash & bank balances1,224501483308329406
Loans & advances614614527620514436
Total current assets7,0605,7775,3204,4084,0173,649
Total current liabilities3,5192,2232,2611,6911,6141,898
Net working capital3,5413,5543,0592,7172,4031,751
Total assets14,08813,20612,82212,61210,9918,780
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash18221953.2385.18262152
Net cash from operating activities1,6538921,005484766598
Net cash from investing activities(820)(488)(416)(1,334)(1,737)(4,464)
Net cash from financing activities(38.98)(441)(422)8187943,977
Net change in cash794(36.87)166(31.95)(177)110
Closing cash1,224501483308329406
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA growth-51.3%+27.5%+82.4%-33.5%-34.6%-
PBT growth-+131.3%+9998.0%--48.9%+9997.0%
Net income growth-451.5%+461.1%+108.5%-148.4%-53.0%-
Revenue CAGR (3Y)+7.8%+11.7%+9.0%---
EBITDA CAGR (3Y)+4.3%+15.6%-7.4%---
Profitability & leverage
Net income margin-3.7%+1.0%+0.2%-2.6%+5.7%+13.2%
Return on capital employed+2.5%+6.4%+5.4%+1.9%+6.9%+12.7%
Return on net worth-3.8%+1.1%+0.2%-2.8%+6.1%+14.9%
Debt / equity0.650.600.700.720.580.54
Long-term debt / equity0.480.370.410.460.420.43
Interest cover-267.9567.08114.15-621.1556.9018.51
Efficiency & per share
Fixed asset turnover0.640.730.710.700.740.77
Inventory turnover3.304.084.244.615.015.13
Debtors turnover3.944.084.153.953.904.01
EPS (₹)(2.46)0.690.13(1.56)3.178.40
Dividend per share (₹)0.000.140.110.000.560.00
Book value per share (₹)61.5061.3559.8056.7656.4756.35
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1251,4891,1961,1279701,6901,2481,284
Revenue growth (YoY)+16.0%-11.9%-4.2%-12.2%-8.8%---
Other income11518496.1520218139.5124.70106
Total expenses1,0081,2511,0561,0009261,2731,0291,032
EBITDA11723814012744.33417219253
EBITDA margin+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%+19.7%
Depreciation65.7370.1264.6961.2559.4461.1755.4653.61
Interest16.3619.5016.8420.3823.2330.5629.1729.95
Profit before tax149332155247143364159276
Tax36.0070.2226.0251.0829.4487.0940.6165.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
Other income663207202341225216
Total expenses4,2334,2453,7723,3532,8802,320
Employee cost745736614548448395
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Depreciation256222205192165144
Interest79.9511510711657.294.71
Profit before tax877911508124462687
Tax17722011654.1994.79115
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (₹)5.275.222.960.583.105.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8146,1285,3894,0683,9373,106
Shareholders' funds (net worth)8,1417,4536,7125,2625,1234,101
Secured loans4211,0098961,3131,15490.20
Unsecured loans36523428133610.6984.06
Total debt7861,2431,1771,6491,164174
Total liabilities9,0228,7447,9216,9366,3004,281
Assets
Gross block4,5754,2493,7673,5653,2252,260
Net block3,0362,8942,6122,6022,4391,627
Capital work in progress221327533417405121
Investments3,5803,1051,7081,7471,6301,592
Inventories1,8731,2051,153819536421
Sundry debtors1,4061,6671,331910989840
Cash & bank balances57417824264.16137152
Loans & advances451486504456403355
Total current assets4,3053,5363,2302,2492,0651,768
Total current liabilities2,4621,4341,4339128991,305
Net working capital1,8422,1011,7971,3371,166463
Total assets9,0228,7447,9216,9366,3004,281
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16422954.281281470.74
Net cash from operating activities1,32854935871.5224934.72
Net cash from investing activities(318)(552)(635)(435)(1,165)(4,383)
Net cash from financing activities(615)(61.74)4512908964,494
Net change in cash395(64.93)175(73.41)(19.03)146
Closing cash57417824264.16137152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA growth-47.2%+68.4%+582.3%-80.3%-25.7%-
PBT growth-3.8%+79.5%+310.4%-73.3%-32.7%+9997.0%
Net income growth+11.4%+77.6%+434.0%-80.8%-32.0%-
Revenue CAGR (3Y)+11.6%+16.5%+14.3%---
EBITDA CAGR (3Y)+82.4%+31.3%-0.1%---
Profitability & leverage
Net income margin+14.6%+13.1%+8.9%+2.0%+11.0%+19.5%
Return on capital employed+10.8%+12.3%+8.3%+3.6%+9.8%+16.2%
Return on net worth+9.0%+9.8%+6.5%+1.3%+8.0%+13.9%
Debt / equity0.130.170.240.270.150.04
Long-term debt / equity0.050.050.080.110.050.00
Interest cover27.1914.0025.95-114.1519.430.99
Efficiency & per share
Fixed asset turnover1.081.321.201.011.221.30
Inventory turnover3.114.484.455.096.996.98
Debtors turnover3.113.533.923.633.653.50
EPS (₹)5.275.222.960.583.105.75
Dividend per share (₹)0.000.140.110.000.560.00
Book value per share (₹)61.3456.2750.7444.0943.2041.23

Timeline of Piramal Pharma

3 dated milestones of Piramal Pharma across 26 years, from founding to its latest funding, stage changes and deals.

  1. Founded Piramal Pharma is founded.
  2. Funding First funding round.
  3. IPO Lists on the stock exchange (IPO).

Web traffic of Piramal Pharma

The website of Piramal Pharma (piramalpharma.com) receives about 19.3K visits a month.

  • Monthly visits
    19.3K

    ▲ 5.2% vs previous month

Similar websites

Websites whose visitors overlap most with Piramal Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Shyam Advisory
shyamadvisory.com
100%
#3,412,311View details
Capital Market
capitalmarket.com
100%
81.2K#358,709View details
Mankind Pharma
mankindpharma.com
71%
92.6K#467,650View details
Piramal Group
piramal.com
32%
47K#586,886View details
Piramal Pharma Solutions
piramalpharmasolutions.com
32%
15.7KView details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Piramal Pharma

Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility
Business Standard • 16 days ago
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility - The Wire
The Wire • 16 days ago
Piramal Pharma Solutions Launches New Microbiology Laboratory at Lexington Facility
WebDisclosure • 16 days ago
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month - The Wire
The Wire • 21 days ago
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Business Standard • 21 days ago
Piramal Pharma Solutions receives $1.75M from Ontario to boost life sciences innovation at Aurora facility
PR Newswire • 21 days ago
Piramal Pharma Solutions' Aurora site receives CAD 1.75M from Ontario's Life Sciences Scale-Up Fund
PR Newswire • 21 days ago
Piramal Pharma: Sales Deal With Bayer Pharmaceuticals Ends December 31, 2026, Without Renewal.
Exchange Update • 21 days ago
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility
Business Standard • 22 days ago
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility - The Wire
The Wire • 22 days ago
Premium access

Complete news archive for Piramal Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Piramal Pharma

Piramal Pharma was founded in 1996 and raised its 1st funding round 24 years after it was founded.

Piramal Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Peter De Young is the CEO of Piramal Pharma, as recorded in our data.

Piramal Pharma has 8,560 employees.

The primary company behind Piramal Pharma, Piramal Pharma Limited, reported revenue of ₹9,161 Cr for FY 2026, down 3% year on year.

Piramal Pharma was established in 1996 in Mumbai, India, as a global pharmaceutical entity. Operations span multiple facilities where a diverse range of products and services is manufactured and supplied. Focus is placed on differentiated pharmaceutical offerings within the healthcare sector. End-to-end capabilities support innovation in drug development and production across international markets.

Piramal Pharma offers Pharma Solutions, Critical Care, and Consumer Healthcare.

Yes, Piramal Pharma is publicly traded on NSE under the ticker symbol PPLPHARMA.

Piramal Pharma operates through Piramal Pharma Limited.

The legal entities of Piramal Pharma currently have 11 directors, including Peter D Deyoung, Ramadorai Subramanian, Jairaj Manohar Purandare and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available